Skip to main content
TipRanks
Go Ultimate75% OFF

Bioventix (BVXP) AI Stock Analysis

17 Followers
GB:BVXP

Bioventix

(LSE:BVXP)

Select Model
Rating:81Outperform
Price Target:GBX 2,298.00â–²(16.65% Upside)
Action:reiterated
Date:10/28/26

The overall score of 81 is driven primarily by the company's outstanding financial health, characterized by best-in-class margins, a debt-free balance sheet, and flawless cash conversion. A very attractive 7.5% dividend yield and reasonable P/E ratio further support the valuation. The main risk is the recent stall in revenue growth, which prevents a higher score. Technicals confirm a strong uptrend, though near-term momentum indicators suggest caution.

Positive Factors
Exceptional profitabilityExceptionally high and stable margins indicate strong earnings power in Bioventix’s antibody and diagnostic-reagent model. Sustained profitability provides internal funding for operations and shareholder returns, while creating resilience if revenue growth remains modest over the next several quarters.
Negative Factors
Recent revenue slowdownThe shift from positive revenue growth in 2021–2024 to slight contraction in 2025 and modest growth in 2026 signals weaker top-line momentum. If sustained, slower growth could limit operating leverage, reduce expansion opportunities, and place greater reliance on existing margins.

Bioventix (BVXP) vs. iShares MSCI United Kingdom ETF (EWC)

-40%-30%-20%-10%0%10%20%30%GB:BVXP-0.90%EWC+21.04%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
GBP 102.93M
Dividend Yield
7.61%
Average Volume (3M)
15.85K
Price to Earnings (P/E)
13.6
Beta (1Y)
0.59
Revenue Growth
-1.10%
EPS Growth
0.32%
Country
UK
Employees
12
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Bioventix Business Overview & Revenue Model

Company Description

Bioventix PLC focuses on the development, manufacturing, and global provision of sheep monoclonal antibodies (SMAs) for various diagnostic purposes. The company's extensive product line features purified SMAs that facilitate testing for critical area...

Bioventix Financial Statement Overview

Summary

Exceptional profitability with 90%+ gross margins and a fortress balance sheet with virtually no debt. Cash conversion exceeds 99%. The score is tempered by recent revenue stagnation and a slight -3.6% annual decline.

Income Statement

78Positive

Balance Sheet

95Very Positive

Cash Flow

88Very Positive
Financial statement breakdown
BreakdownTTMJun 2025Jun 2024Jun 2023Jun 2022Jun 2021
Income Statement
Total Revenue12.97M12.97M13.12M13.61M12.82M11.72M
Gross Profit11.81M11.81M11.92M12.68M11.86M10.87M
EBITDA9.79M9.79M10.17M10.74M10.20M9.42M
Net Income7.61M7.61M7.58M8.10M8.37M7.67M
Balance Sheet
Total Assets12.83M12.83M12.86M13.73M13.28M13.12M
Cash, Cash Equivalents and Short-Term Investments5.26M5.26M5.08M6.00M5.72M6.13M
Total Debt10.97K10.97K0000
Total Liabilities1.41M1.41M1.31M1.73M1.22M1.30M
Stockholders Equity11.42M11.42M11.55M12.00M12.06M11.82M
Cash Flow
Free Cash Flow8.02M8.02M7.01M8.33M7.89M7.55M
Operating Cash Flow8.09M8.09M7.03M8.34M7.90M7.56M
Investing Cash Flow-71.60K-71.60K173.16K186.06K90.51K-11.76K
Financing Cash Flow-7.84M-7.84M-8.12M-8.25M-8.30M-7.92M

Bioventix Technical Analysis

Technical Analysis SentimentPositive
Last Price1970.00

Price Trends

50DMA1716.60Positive
100DMA1625.35Positive
200DMA1592.90Positive

Market Momentum

MACD67.40Positive
RSI65.47Neutral
STOCH43.16Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:BVXP, the sentiment is Positive. The current price of 1970.00 is above the 20-day moving average (MA) of 1919.80, above the 50-day MA of 1716.60, and above the 200-day MA of 1592.90, indicating a bullish trend. The MACD of 67.40 indicates Positive momentum. The RSI at 65.47 is Neutral, neither overbought nor oversold. The STOCH value of 43.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:BVXP.

Bioventix Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GB:BVXP against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
GB:BVXPGB:BVXP81OutperformGBP 102.93M13.5967.81%7.61%-1.10%0.32%
GB:4BBGB:4BB52NeutralGBP 100.70M-4.53-316.73%―-56.10%-16.77%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
GB:APTAGB:APTA46NeutralGBP 12.66M-12.17-46.61%―28.35%57.14%
GB:AVCTGB:AVCT40UnderperformGBP 287.20M-6.47-1293.07%―――
GB:FABGB:FAB40UnderperformGBP 5.32M-4.29-97.87%―7.38%44.13%
GB:OBDGB:OBD40UnderperformGBP 15.46M-0.29-451.74%―33.37%86.41%

* Healthcare Sector Average

Performance Comparison

-50%0%50%GB:BVXPGB:AVCTGB:OBDGB:FABGB:4BBGB:APTADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:BVXP and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:BVXPBioventix plc1970.00-17.97-0.90%
GB:AVCTAvacta Group plc59.00-22.00-27.16%
GB:OBDOxford BioDynamics0.12-0.17-58.93%
GB:FABFusion Antibodies Plc4.25-8.00-65.31%
GB:4BB4basebio UK Societas525.00-187.50-26.32%
GB:APTAAptamer Group Plc0.36-0.57-60.75%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 28, 2026